Search research articles
Contact Us
Filters
Showing results (81-90 of 168) with videos related to
Page
of 17
Sort By:
Oncogene
|
August 6, 2013
Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells
D Raina, Y Uchida, A Kharbanda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer
Y Wu, M M Amonkar, B H Sherrill, et al.
Cancer
|
March 5, 1998
Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma
A Ribas, J Albanell, L A Solé-Calvo, et al.
British Journal of Cancer
|
February 25, 2009
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
S Rao, N Starling, D Cunningham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 17, 2011
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer
Y Wu, M M Amonkar, B H Sherrill, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 23, 2013
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer
J Cortés, J Baselga, Y-H Im, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2002
Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors
E Díaz-Rubio, T R J Evans, J Tabemero, et al.
British Journal of Cancer
|
May 6, 2008
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study
A Awada, J Albanell, P A Canney, et al.
Oncogene
|
August 26, 1998
FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas
W J Maerz, J Baselga, V E Reuter, et al.
Oncogene
|
December 1, 1993
Over-expression of transforming growth factor alpha antagonizes the anti-tumorigenic but not the differentiation actions of retinoic acid in a human teratocarcinoma cell
J Baselga, W J Maerz, D Moy, et al.
Page
of 17
Search research articles
Search
Showing results (81-90 of 168) with videos related to
Sort By:
Page
of 17
Oncogene
|
August 6, 2013
Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells
D Raina, Y Uchida, A Kharbanda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer
Y Wu, M M Amonkar, B H Sherrill, et al.
Cancer
|
March 5, 1998
Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma
A Ribas, J Albanell, L A Solé-Calvo, et al.
British Journal of Cancer
|
February 25, 2009
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
S Rao, N Starling, D Cunningham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 17, 2011
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer
Y Wu, M M Amonkar, B H Sherrill, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 23, 2013
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer
J Cortés, J Baselga, Y-H Im, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2002
Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors
E Díaz-Rubio, T R J Evans, J Tabemero, et al.
British Journal of Cancer
|
May 6, 2008
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study
A Awada, J Albanell, P A Canney, et al.
Oncogene
|
August 26, 1998
FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas
W J Maerz, J Baselga, V E Reuter, et al.
Oncogene
|
December 1, 1993
Over-expression of transforming growth factor alpha antagonizes the anti-tumorigenic but not the differentiation actions of retinoic acid in a human teratocarcinoma cell
J Baselga, W J Maerz, D Moy, et al.
Page
of 17